Biopharmaceutical firm Lundbeck A/S announced that it would discontinue future research into its experimental stroke drug compound desmoteplase, despite two previous studies showing positive patient effects and fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke.
Lundbeck would take a write down of $51.26 million for the fourth quarter of 2014, despite giving no other info on the stoppage except that it was “insufficiently clear how to select patients in future prospective studies.”
“Lundbeck has decided to cease further development in ischemic stroke,” said the company in a statement. “Alternatives including divestiture are now being evaluated.”
Advertisement
